Search research articles
Contact Us
Filters
Showing results (111-120 of 153) with videos related to
Page
of 16
Sort By:
Clinical Hematology International
|
January 19, 2023
Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple Myeloma
Torben Plesner, Simon J Harrison, Hang Quach, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
June 19, 2019
Renal Impairment at Diagnosis in Myeloma: Patient Characteristics, Treatment, and Impact on Outcomes. Results From the Australia and New Zealand Myeloma and Related Diseases Registry
P Joy Ho, Elizabeth M Moore, Zoe K McQuilten, et al.
Internal Medicine Journal
|
May 30, 2026
Australian clinical practice guideline: diagnosis and treatment of idiopathic multicentric Castleman disease
Dipti Talaulikar, Jun Yen Ng, Adam Bryant, et al.
Leukemia & Lymphoma
|
April 15, 2014
The utility and limitations of (18)F-fluorodeoxyglucose positron emission tomography with computed tomography in patients with primary mediastinal B-cell lymphoma: single institution experience and literature review
Chan Y Cheah, Michael S Hofman, John F Seymour, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 21, 2019
Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab in High-Risk Smoldering Multiple Myeloma
Timothy A Brighton, Amit Khot, Simon J Harrison, et al.
The Lancet. Haematology
|
June 30, 2025
Venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed or refractory multiple myeloma (BELLINI): final overall survival results from a randomised, phase 3 study
Shaji K Kumar, Simon J Harrison, Michele Cavo, et al.
British Journal of Haematology
|
May 26, 2021
Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics
Simon J Harrison, Aurore Perrot, Adrian Alegre, et al.
Blood Cancer Journal
|
August 12, 2024
Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma
Rajshekhar Chakraborty, Heloise Cheruvalath, Anannya Patwari, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases
|
June 24, 2026
Persistent and pathogen-specific infection risk during long-term survivorship after CD19 CAR-T: An Australian multi-centre cohort study
Gemma K Reynolds, Mark R Dowling, Safia Belbachir, et al.
Cancer Epidemiology
|
May 16, 2025
Allergic disease and risk of multiple myeloma: A case-control study
Simon Cheah, Adrian J Lowe, Nina Afshar, et al.
Page
of 16
Search research articles
Search
Showing results (111-120 of 153) with videos related to
Sort By:
Page
of 16
Clinical Hematology International
|
January 19, 2023
Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple Myeloma
Torben Plesner, Simon J Harrison, Hang Quach, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
June 19, 2019
Renal Impairment at Diagnosis in Myeloma: Patient Characteristics, Treatment, and Impact on Outcomes. Results From the Australia and New Zealand Myeloma and Related Diseases Registry
P Joy Ho, Elizabeth M Moore, Zoe K McQuilten, et al.
Internal Medicine Journal
|
May 30, 2026
Australian clinical practice guideline: diagnosis and treatment of idiopathic multicentric Castleman disease
Dipti Talaulikar, Jun Yen Ng, Adam Bryant, et al.
Leukemia & Lymphoma
|
April 15, 2014
The utility and limitations of (18)F-fluorodeoxyglucose positron emission tomography with computed tomography in patients with primary mediastinal B-cell lymphoma: single institution experience and literature review
Chan Y Cheah, Michael S Hofman, John F Seymour, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 21, 2019
Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab in High-Risk Smoldering Multiple Myeloma
Timothy A Brighton, Amit Khot, Simon J Harrison, et al.
The Lancet. Haematology
|
June 30, 2025
Venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed or refractory multiple myeloma (BELLINI): final overall survival results from a randomised, phase 3 study
Shaji K Kumar, Simon J Harrison, Michele Cavo, et al.
British Journal of Haematology
|
May 26, 2021
Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics
Simon J Harrison, Aurore Perrot, Adrian Alegre, et al.
Blood Cancer Journal
|
August 12, 2024
Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma
Rajshekhar Chakraborty, Heloise Cheruvalath, Anannya Patwari, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases
|
June 24, 2026
Persistent and pathogen-specific infection risk during long-term survivorship after CD19 CAR-T: An Australian multi-centre cohort study
Gemma K Reynolds, Mark R Dowling, Safia Belbachir, et al.
Cancer Epidemiology
|
May 16, 2025
Allergic disease and risk of multiple myeloma: A case-control study
Simon Cheah, Adrian J Lowe, Nina Afshar, et al.
Page
of 16